Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$11.69 USD

11.69
3,348,376

+3.39 (40.84%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $11.84 +0.15 (1.28%) 7:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AGEN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Agenus Inc. [AGEN]

Reports for Purchase

Showing records 1 - 20 ( 257 total )

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/14/2024

Company Report

Pages: 5

4Q23 Recap: 2024 to Mark a Pivotal Year For Agenus With Potential First Bot/Bal BLA Filing

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

01/16/2024

Industry Report

Pages: 9

Takeaways From Our Meetings at JPM

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/07/2023

Company Report

Pages: 5

3Q23 Recap: Multiple Data Readouts and BLA Filings Anticipated in 2024; Potential Bot/Bal Partnership on the Horizon

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

10/23/2023

Company Report

Pages: 7

ESMO Data Updates Validate That Agenus Could Be the Next Big IO Play

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/08/2023

Company Report

Pages: 5

2Q23 Recap: Next Significant Catalyst Could Be NSCLC Data Update in 2H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

07/03/2023

Company Report

Pages: 4

Bot/Bal Phase 1b OS Data Impress in MSS-CRC Patients, Increasing Our Confidence in Phase 2 Success

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

06/05/2023

Company Report

Pages: 4

AGEN2373 Data Surprise to the Upside; Gotistobart Data Validate CTLA-4 Efficacy in NSCLC

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

05/09/2023

Company Report

Pages: 6

1Q23 Take: Pipeline Progress Continues With Multiple Data Presentations and Study Initiations on Track for 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

03/27/2023

Company Report

Pages: 7

Bot/Bal Combination Continues to Demonstrate Responses in Ovarian Cancer Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

03/14/2023

Company Report

Pages: 5

4Q22 Take: Botensilimab Continues to Demonstrate Positive Results in Cold Tumors With NSCLC Taking the Stage

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

02/28/2023

Company Report

Pages: 74

Botensilimab Could be the Next Big IO Play; Assuming at Buy and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 75.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/02/2022

Company Report

Pages: 5

Agenus Reported FY2021 Results; 2022 May Be An Inflection Year; Reiterate Buy and Increase PT from $12 to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

12/16/2021

Company Report

Pages: 48

Is Agenus the Most Under the Radar Biotech in I/O? Initiate at Buy and $12 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 50.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for AGEN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

08/04/2020

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

07/27/2020

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

07/14/2020

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

06/12/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party